0 CHECKOUT

CEL-SCI Corporation - Product Pipeline Review - 2015

  • ID: 3259634
  • April 2015
  • 40 pages
  • Global Markets Direct
1 of 3

CEL-SCI Corporation - Product Pipeline Review - 2015

Summary

This, ‘CEL-SCI Corporation - Product Pipeline Review - 2015’, provides an overview of the CEL-SCI Corporation’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CEL-SCI Corporation’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent READ MORE >

Note: Product cover images may vary from those shown
2 of 3

List of Tables
List of Figures
CEL-SCI Corporation Snapshot
CEL-SCI Corporation Overview
Key Information
Key Facts
CEL-SCI Corporation - Research and Development Overview
Key Therapeutic Areas
CEL-SCI Corporation - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
CEL-SCI Corporation - Pipeline Products Glance
CEL-SCI Corporation - Late Stage Pipeline Products
Phase III Products/Combination Treatment Modalities
CEL-SCI Corporation - Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
CEL-SCI Corporation - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
CEL-SCI Corporation - Drug Profiles
Leukocyte Interleukin
Product Description
Mechanism of Action
R&D Progress
LEAPS-H1N1-DC
Product Description
Mechanism of Action
R&D Progress
CEL-1000
Product Description
Mechanism of Action
R&D Progress
CEL-2000
Product Description
Mechanism of Action
R&D Progress
Vaccine for Breast Cancer
Product Description
Mechanism of Action
R&D Progress
CEL-SCI Corporation - Pipeline Analysis
CEL-SCI Corporation - Pipeline Products by Target
CEL-SCI Corporation - Pipeline Products by Route of Administration
CEL-SCI Corporation - Pipeline Products by Molecule Type
CEL-SCI Corporation - Pipeline Products by Mechanism of Action
CEL-SCI Corporation - Recent Pipeline Updates
CEL-SCI Corporation - Dormant Projects
CEL-SCI Corporation - Dormant Projects
CEL-SCI Corporation - Company Statement
CEL-SCI Corporation - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
CEL-SCI Corporation, Key Information
CEL-SCI Corporation, Key Facts
CEL-SCI Corporation - Pipeline by Indication, 2015
CEL-SCI Corporation - Pipeline by Stage of Development, 2015
CEL-SCI Corporation - Monotherapy Products in Pipeline, 2015
CEL-SCI Corporation - Phase III, 2015
CEL-SCI Corporation - Phase I, 2015
CEL-SCI Corporation - Preclinical, 2015
CEL-SCI Corporation - Pipeline by Target, 2015
CEL-SCI Corporation - Pipeline by Route of Administration, 2015
CEL-SCI Corporation - Pipeline by Molecule Type, 2015
CEL-SCI Corporation - Pipeline Products by Mechanism of Action, 2015
CEL-SCI Corporation - Recent Pipeline Updates, 2015
CEL-SCI Corporation - Dormant Developmental Projects,2015
CEL-SCI Corporation, Subsidiaries

List of Figures
CEL-SCI Corporation - Pipeline by Top 10 Indication, 2015
CEL-SCI Corporation - Pipeline by Stage of Development, 2015
CEL-SCI Corporation - Monotherapy Products in Pipeline, 2015
CEL-SCI Corporation - Pipeline by Top 10 Target, 2015
CEL-SCI Corporation - Pipeline by Top 10 Route of Administration, 2015
CEL-SCI Corporation - Pipeline by Top 10 Molecule Type, 2015

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.